法舒地尔治疗肺心病的临床疗效及对血hs-CRP、NT-proBNP的影响

Clinical therapeutic effect of fasudil in treatment of pulmonary heart disease and its effect on blood hs-CRP and NT-proBNP

目的探讨法舒地尔治疗肺心病的临床疗效以及对患者血hs-CRP、NT-proBNP的影响。方法选取2015年2月至2016年3月在我院接受治疗的肺心病患者90例,采用随机数表法将患者分为观察组和对照组,每组均为45例,观察组患者给予法舒地尔治疗,对照组患者给予常规治疗,观察两组患者治疗前后心功能指标、肺功能指标以及hs-CRP、NT-proBNP以及肺动脉收缩压等指标改善情况,同时比较两组患者治疗后的临床疗效。结果治疗后,两组患者的hs-CRP以及NT-proBNP表达水平都有所降低,观察组(19.12±3.89ng/L、45.23±10.25ng/L)低于对照组(25.12±4.02ng/L、56.12±9.89ng/L),两组比较差异显著(P<0.05);治疗后,两组患者的LVEF表达水平均有升高,观察组高于对照组,两组比较差异显著(P<0.05);治疗后,观察组患者的LVEDD以及LAD表达水平都有降低,且低于对照组,两组比较差异显著(P<0.05);治疗后,两组患者的SaO_2都有所升高,观察组高于对照组,具有统计学意义(P<0.05);治疗后,观察组患者的肺动脉收缩压有所降低且低于对照组,两组比较差异显著(P<0.05);治疗后,观察组患者的PaO_2水平表达(78.23±12.02mmHg)高于对照组(65.89±11.45mmHg),PaCO_2水平表达(56.12±8.23mmHg)低于对照组(63.89±8.12mmHg),两组比较差异显著(P<0.05);观察组患者治疗后的总有效率为95.56%高于对照组75.56%,两组比较差异显著(P<0.05)。结论给予肺心病患者法舒地尔治疗,能够有效改善患者的临床疗效,同时也能够显著降低患者的hs-CRP以及NT-proBNP的水平表达,值得临床推广使用。

Objective To investigate the clinical efficacy of fasudil in treatment of pulmonary heart disease and its effect on blood hs-CRP and NT-proBNP. Methods 90 patients with pulmonary heart disease from February2015 to March 2016 in our hospital were randomly were randomly divided into observation group and control group,and each group had 45 cases. The observation group was treated with fasudil,and the control group was given routine treatment. Their cardiac function index,pulmonary function,hs-CRP,NT-proBNP,and the index of pulmonary artery systolic pressure and other indicators were compared between the two groups before and after treatment. Results After treatment,the levels of hs-CRP and NT-proBNP decreased,and they were( 19. 12 ± 3. 89 ng/L,45. 23 ±10. 25 ng/L) in the observation group and( 25. 12 ± 4. 02 ng/L,56. 12 ± 9. 89 ng/L) in the control group( P <0. 05). The expression of LVEF was elevated,and it was higher in the observation group than in the control group( P< 0. 05). The expression of LVEDD and LAD decreased in the observation group,and it was obviously lower than that in the control group( P < 0. 05). The value of SaO2 increased in the two groups,and the observation group was statistically higher than the control group( P < 0. 05). Their pulmonary artery systolic pressure decreased in the two groups,and it was lower in the observation group than in the control group( P < 0. 05). The levels of PaO2 and PaCO2 were( 78. 23 ± 12. 02 mmHg) and( 56. 12 ± 8. 23 mmHg) in the observation group and( 65. 89 ±11. 45 mmHg) and( 63. 89 ± 8. 12 mmHg) in the control group( P < 0. 05). The total effective rate was 95. 56% in the observation group,which was obviously higher than 75. 56% in the control group( P < 0. 05). Conclusion Fasudil can effectively improve their clinical effect,and reduce hs-CRP and NT-proBNP expression in treatment of pulmonary heart disease patients,which is worthy of widely clinical application.